 |
|||||
|
|||||
|
Confirmed title: On-boarding new technologies into existing discovery outsourcing partnerships
|
|||||
|
19 June: 09:30 - 10:00
|
|||||
|
Dr Christoph Rosenbohm, Head of Discovery Ops, Roche Innovation Center Copenhagen
|
|||||
|
ABSTRACT
|
|||||
|
Dr. Christoph Rosenbohm will speak about the opportunities and challenges encountered when a “mature” technology in a well-established CMO partnership needs to change. New compounds that need to be made as custom manufacturing are entering the partnership and the established compounds LNA phosphoramidites are becoming commodities with other vendors entering into the supplier landscape.
|
|||||
|
BIOGRAPHY
|
|||||
|
Head of Discovery Operations, RNA Molecule Research (RMR)
Pharma Research and Early Discovery (pRED) Roche Innovation Center Copenhagen (RICC) As Head of Discovery Operations, RMR Christoph is responsible for leading the Oligonucleotides synthesis, Pharmacology, and Screening Operations teams and as a member of the RMR-LT he participates in defining and setting the strategy for RMR. Christoph holds a Master of Science and a Ph.D. in Organic Chemistry from the University of Southern Denmark (the lab of Prof. Jesper Wengel - one of the inventors of LNA). After his PhD, Christoph worked as a post-doctoral fellow at the Danish Technical Univerisity. In addition Christoph holds an executive MBA in Technology, Market and Organisation from Copenhagen Business School. Christoph started his biotech career in Cureon as chemist with the task of synthesizing the LNA monomers. The company was later merged with Pantheco A/S to create Santaris Pharma A/S in 2003, where he become group leader for the chemistry team. Later the group was joined with CMC, Bioinformatics, PK and Pharmacolgy to form the Research Operation Department for which he became the director. A position he held until the acquisition by Roche in 2014. |
|||||
|
COMPANY PROFILE
|
|||||
|
Roche Innovation Center Copenhagen
|
|||||
|
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. https://www.roche.com/research_and_development.htm Roche Innovation Center Copenhagen (RICC) is the home of RNA Molecule Research in Roche pRED, and is leading in the rapidly growing field of RNA targeted therapeutics. RICC is using the LNA platform to develop new therapeutics across several area. |
